These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28278515)

  • 1. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
    Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG
    Br J Cancer; 2017 Apr; 116(8):1002-1011. PubMed ID: 28278515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
    Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L
    Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.
    Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; PRIMe Consortium ; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG
    Int J Cancer; 2017 Nov; 141(10):2112-2120. PubMed ID: 28741687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
    Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
    Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
    Zedan AH; Osther PJS; Assenholt J; Madsen JS; Hansen TF
    Sci Rep; 2020 Jan; 10(1):227. PubMed ID: 31937854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.
    Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ;
    Br J Cancer; 2014 Oct; 111(9):1802-9. PubMed ID: 25144624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
    Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
    Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
    Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
    Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
    Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
    Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
    Pimenta RC; Viana NI; Amaral GQ; Park R; Morais DR; Pontes J; Guimaraes VR; Camargo JA; Leite KR; Nahas WC; Srougi M; Reis ST
    Tumour Biol; 2018 Nov; 40(11):1010428318803011. PubMed ID: 30400755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
    Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
    Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    Montgomery B; Kheoh T; Molina A; Li J; Bellmunt J; Tran N; Loriot Y; Efstathiou E; Ryan CJ; Scher HI; de Bono JS
    Eur Urol; 2015 May; 67(5):866-73. PubMed ID: 25018037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cfDNA as a Prognostic Marker of Response to Taxane Based Chemotherapy in Patients with Prostate Cancer.
    Kienel A; Porres D; Heidenreich A; Pfister D
    J Urol; 2015 Oct; 194(4):966-71. PubMed ID: 25896555
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Kaikkonen E; Ettala O; Nikulainen I; Taimen P; Lehtinen I; Boström PJ; Kellokumpu-Lehtinen PL; Schleutker J
    Anticancer Res; 2019 Oct; 39(10):5353-5359. PubMed ID: 31570429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
    Corcoran C; Rani S; O'Driscoll L
    Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.